Insight, China's Pharmaceutical Industry

Yantai Dongcheng Secures NMPA Approval for 225Ac‑LNC1011 Alpha‑Particle Radiopharmaceutical to Target Prostate Cancer

China‑based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) announced that its investigational 225Ac‑LNC1011 injection...

Company

Eli Lilly Announces $6.5 B Houston Facility to Boost Synthetic‑Medicine API Production

Fineline Cube Sep 24, 2025

Eli Lilly (NYSE: LLY) announced today that it will construct a new $6.5 billion manufacturing complex...

Company Drug

Sino Biopharmaceutical Reports First‑Patient Enrollment for LM‑2417 Phase I Trial

Fineline Cube Sep 24, 2025

China‑based Sino Biopharmaceutical (HKG: 1177) announced today that its internally‑developed Class 1 innovative drug LM‑2417 has...

Company Deals

MSD Teams with Variational AI in $349 Million Generative‑AI Drug Discovery Deal

Fineline Cube Sep 24, 2025

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has struck a $349 million partnership with Canada‑based...

Company Deals

ProBio and Immunofoco Forge Global CGT Manufacturing Alliance

Fineline Cube Sep 23, 2025

ProBio, a subsidiary of GenScript Biotech Corporation (HKG: 1548), and China‑based Immunofoco have inked a...

Company Drug

Stealth BioTherapeutics Receives FDA Accelerated Approval for Forzinity in Barth Syndrome

Fineline Cube Sep 23, 2025

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Stealth BioTherapeutics’ Forzinity (elamipretide)...

Policy / Regulatory

China Drug Procurement: Centralized Rules Shape 11th Round Of VBP

Fineline Cube Sep 23, 2025

The Joint Procurement Office of the National Healthcare Security Administration (NHSA) published the definitive rules...

Company Deals Drug

Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS

Fineline Cube Sep 23, 2025

China‑based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd....

Company Drug

Roche’s SC Lunsumio Gains CHMP Recommendation for Relapsed Follicular Lymphoma

Fineline Cube Sep 23, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the European Medicines Agency’s Committee for Medicinal Products...

Company Drug

Roche’s giredestrant Yields Positive PFS Results in evERA Phase III Study

Fineline Cube Sep 23, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Phase III evERA trial has met both co‑primary...

Medical Device

Shanghai Sanyou Medical’s Agloe Robot Enters Chinese NMPA Special Review for Innovative Spine Devices

Fineline Cube Sep 23, 2025

Shanghai Sanyou Medical Co., Ltd. (SHA: 688085) announced that its affiliate Agloe Medical Technologies has...

Company Drug

Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR

Fineline Cube Sep 23, 2025

Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau‑protein antibody etalanetug (E2814) has...

Company Deals Drug

Pfizer to Acquire Metsera for $4.9 B, Expanding Its Obesity & Cardiometabolic Pipeline

Fineline Cube Sep 23, 2025

Pfizer Inc. (NYSE: PFE) announced today that it will acquire Metsera, Inc. (NASDAQ: MTSR), a...

Company Drug

Youcare Pharma Secures FDA Approval for YKYY013, a Novel siRNA Therapy for Chronic Hepatitis B

Fineline Cube Sep 23, 2025

Youcare Pharmaceutical Group (SHA: 688658) announced that the U.S. Food and Drug Administration (FDA) has...

Policy / Regulatory

National Healthcare Security Administration Announces Nationwide Pilot for Real‑World Medical‑Insurance Value Evaluation

Fineline Cube Sep 23, 2025

The National Healthcare Security Administration (NHSA) today issued a notice outlining a multi‑city pilot program...

Company Drug

Huadong Medicine Secures FDA IND Approval for HDM2017 ADC

Fineline Cube Sep 23, 2025

Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration...

Company Drug

Sichuan Kelun‑Biotech’s A400 Receives NDA Acceptance in China

Fineline Cube Sep 23, 2025

Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the Center for Drug Evaluation...

Company Drug

Visen Pharmaceuticals Secures Hainan Approval for Palopegteriparatide

Fineline Cube Sep 23, 2025

Visen Pharmaceuticals (HKG: 2561) announced today that its innovative drug palopegteriparatide (TransCon PTH) has received official...

Company Drug

Stone Pharmaceuticals Launches CS2009 Phase II Trial in Australia

Fineline Cube Sep 23, 2025

CStone Pharmaceuticals (HKG: 2616) announced today that the first patient has been dosed in Australia...

Company Drug

Nanjing Leads Biolabs Secures FDA IND for LBL‑047, a First‑In‑Class Bispecific Fusion Protein

Fineline Cube Sep 23, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the U.S. Food and Drug...

Insight, China's Pharmaceutical Industry

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Yantai Dongcheng Secures NMPA Approval for 225Ac‑LNC1011 Alpha‑Particle Radiopharmaceutical to Target Prostate Cancer

Eli Lilly Announces $6.5 B Houston Facility to Boost Synthetic‑Medicine API Production

Sino Biopharmaceutical Reports First‑Patient Enrollment for LM‑2417 Phase I Trial

MSD Teams with Variational AI in $349 Million Generative‑AI Drug Discovery Deal

ProBio and Immunofoco Forge Global CGT Manufacturing Alliance

Stealth BioTherapeutics Receives FDA Accelerated Approval for Forzinity in Barth Syndrome

China Drug Procurement: Centralized Rules Shape 11th Round Of VBP

Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS

Roche’s SC Lunsumio Gains CHMP Recommendation for Relapsed Follicular Lymphoma

Roche’s giredestrant Yields Positive PFS Results in evERA Phase III Study

Shanghai Sanyou Medical’s Agloe Robot Enters Chinese NMPA Special Review for Innovative Spine Devices

Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR

Pfizer to Acquire Metsera for $4.9 B, Expanding Its Obesity & Cardiometabolic Pipeline

Youcare Pharma Secures FDA Approval for YKYY013, a Novel siRNA Therapy for Chronic Hepatitis B

National Healthcare Security Administration Announces Nationwide Pilot for Real‑World Medical‑Insurance Value Evaluation

Huadong Medicine Secures FDA IND Approval for HDM2017 ADC

Sichuan Kelun‑Biotech’s A400 Receives NDA Acceptance in China

Visen Pharmaceuticals Secures Hainan Approval for Palopegteriparatide

Stone Pharmaceuticals Launches CS2009 Phase II Trial in Australia

Nanjing Leads Biolabs Secures FDA IND for LBL‑047, a First‑In‑Class Bispecific Fusion Protein

You Missed

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC